News & Updates

Findings from the RESCUE BT2 study support the potential of tirofiban to improve neurologic outcomes than aspirin in patients with acute ischaemic stroke without visible large or medium vessel occlusion (LVO or MVO) within 24 hours of last known well or of onset of stroke symptom progression. However, its efficacy was countered by the higher rate of symptomatic intracranial haemorrhage (sICH).

Not a lot of individuals, especially women, are initiated on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after a transient ischaemic attack or minor acute ischaemic stroke, and this is despite evidence showing that such a strategy may prevent a second and potentially more serious stroke, as reported in a study presented at ISC 2023.

Treatment with stereotactic body radiation therapy (SBRT) followed by sorafenib results in better overall (OS) and progression-free survival (PFS), with no increase in adverse events (AEs), compared with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC), as shown in a phase III study presented at the 2023 ASCO GI Cancers Symposium.

Butylphthalide, a novel medication that contains a compound found in celery, appears to help with functional recovery in patients with ischaemic stroke, as shown in a study presented at ISC 2023.